Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EBIT (2020 - 2026)

Immuneering's EBIT history spans 7 years, with the latest figure at -$15.3 million for Q1 2026.

  • On a quarterly basis, EBIT rose 0.97% to -$15.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$59.2 million, a 7.79% increase, with the full-year FY2025 number at -$59.4 million, up 7.33% from a year prior.
  • EBIT came in at -$15.3 million for Q1 2026, down from -$13.8 million in the prior quarter.
  • The five-year high for EBIT was -$11.6 million in Q2 2022, with the low at -$18.6 million in Q4 2024.
  • Historically, EBIT has averaged -$14.6 million across 5 years, with a median of -$14.8 million in 2025.
  • Biggest five-year swings in EBIT: plummeted 107.27% in 2022 and later rose 25.89% in 2025.
  • Year by year, EBIT stood at -$14.0 million in 2022, then decreased by 16.57% to -$16.3 million in 2023, then decreased by 13.84% to -$18.6 million in 2024, then increased by 25.89% to -$13.8 million in 2025, then decreased by 11.51% to -$15.3 million in 2026.
  • Business Quant data shows EBIT for IMRX at -$15.3 million in Q1 2026, -$13.8 million in Q4 2025, and -$15.4 million in Q3 2025.